[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590381":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":38,"responsibleParty":59,"collaborators":31,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":31,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":31,"enrollmentInfo":71,"targetDuration":31,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":31,"overallStatus":40,"whyStopped":31,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intracoronary tirofiban group","EXPERIMENTAL","Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg\u002Fkg)",[13],"Drug: Intracoronary tirofiban",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Patients will receive intracoronary saline 0.9% solution as a control group.",[19],"Drug: Saline 0.9%",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Intracoronary tirofiban","Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg\u002Fkg).",[9],[27],"Aggrastat",{"type":22,"name":29,"description":17,"armGroupLabels":30,"otherNames":31},"Saline 0.9%",[15],null,[33],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Mohammed A Hammad, MD","CONTACT","00201015928694","drhammad879@gmail.com",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Kafr ash Shaykh","Kafrelsheikh","33516","Egypt","EG",{"type":47,"coordinates":48},"Point",[49,50],30.93991,31.11174,{"lat":50,"lon":49},[53,54,57],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},{"name":55,"role":56,"phone":31,"phoneExt":31,"email":31},"Wael A Hassib, MD","PRINCIPAL_INVESTIGATOR",{"name":58,"role":56,"phone":31,"phoneExt":31,"email":31},"Mohamed K Salama, MD",{"type":56,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Mohammed Ali Mohammed Hammad","Lecturer of Cardiology, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh, Egypt.","100590381","no-reflow-in-patients-with-stemi-after-intracoronary-tirofiban-after-opening-of-the-track-100590381",false,"NCT06966674","No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track","Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Both sexes.\n* Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \\>30 minutes with ST-segment elevation of \\>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.\n\nExclusion Criteria:\n\n* Treatment with thrombolytic drugs in the previous 24 hours.\n* Known malignancy.\n* Thrombocytopenia.\n* End-stage liver disease.\n* Cardiogenic shock.\n* Renal failure with glomerular filtration\\\u003C30 ml\u002Fmin.\n* Contraindication for the use of tirofiban.","ALL","18 Years",{"count":72,"type":73},60,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb\u002FIIIa inhibitors after opening of track in thrombus.",[79,80,81,82],"No-Reflow","STEMI","Intracoronary","Tirofiban","2025-05-12",{"date":85,"type":86},"2025-05-13","ACTUAL",{"date":83,"type":86},{"date":89,"type":73},"2025-10-01",{"name":5,"class":6},1]